217 related articles for article (PubMed ID: 390336)
1. Comparison of enteric-coated levodopa with levodopa-carbidopa combination. A double-blind crossover trial.
Gilligan B; Wodak J; Stark R; O'Halloran M
Med J Aust; 1979 Aug; 2(4):205-7. PubMed ID: 390336
[TBL] [Abstract][Full Text] [Related]
2. Sinemet CR in Parkinson's disease.
Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
[TBL] [Abstract][Full Text] [Related]
3. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
4. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
5. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
Ondo WG; Shinawi L; Moore S
Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
[TBL] [Abstract][Full Text] [Related]
6. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
[TBL] [Abstract][Full Text] [Related]
7. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
Mark MH; Sage JI
Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
[TBL] [Abstract][Full Text] [Related]
8. A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
Diamond SG; Markham CH; Treciokas LJ
Ann Neurol; 1978 Mar; 3(3):267-72. PubMed ID: 352236
[TBL] [Abstract][Full Text] [Related]
9. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
Lombardo L; De la Garza R
Arch Invest Med (Mex); 1977; 8(2):123-8. PubMed ID: 907417
[TBL] [Abstract][Full Text] [Related]
11. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
[TBL] [Abstract][Full Text] [Related]
12. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Metman LV; Hoff J; Mouradian MM; Chase TN
Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
Jankovic J; Schwartz K; Vander Linden C
Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215
[TBL] [Abstract][Full Text] [Related]
14. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
LondoƵ R
Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
[TBL] [Abstract][Full Text] [Related]
16. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease.
Savery F
Dis Nerv Syst; 1977 Aug; 38(8):605-8. PubMed ID: 328244
[TBL] [Abstract][Full Text] [Related]
17. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Deleu D; Jacques M; Michotte Y; Ebinger G
Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
[TBL] [Abstract][Full Text] [Related]
18. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease.
Mark MH; Sage JI
Ann Clin Lab Sci; 1989; 19(6):415-21. PubMed ID: 2690730
[TBL] [Abstract][Full Text] [Related]
20. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Wolters EC; Horstink MW; Roos RA; Jansen EN
Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
[No Abstract] [Full Text] [Related]
[Next] [New Search]